PALM SPRINGS, CA — In a Phase 3 study of tapentadol immediate-release (IR) versus oxycodone IR for moderate-to-severe, acute low-back pain with radicular leg pain, tapentadol IR was noninferior to ...
Egalet announced the launch of Oxaydo (oxycodone HCI) tablets, the first immediate-release oxycodone formulation to deter abuse via snorting. Egalet announced the launch of Oxaydo (oxycodone HCI) ...
The Company plans to have RoxyBond 10mg available before the end of the year. The Food and Drug Administration (FDA) has approved RoxyBond ™ (oxycodone hydrochloride) immediate-release (IR) 10 mg ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...
Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Cancer patients who ...
RoxyBond's SentryBond technology enhances resistance to manipulation, reducing abuse potential without aversive agents. Over 2000 in vitro tests and a human abuse potential study validate the ...
Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...
Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Cancer patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results